Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q2 2024 · 10-Q
Revenue$1.28M$1.28Mno prior Q2 2023 on file Net Income-$2.94M-$2.94MN/M vs Q2 2023 EPS Diluted-$0.71-$0.71N/M vs Q2 2023 Operating Income-$3,697,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,231,000N/M Margins · derivedOperating margin-289.1%
Net margin-229.9%
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end